InterMune Licenses Qualyst's Drug Discovery Technology
B-Clear hepatocyte system enables in vitro assessment and in vivo prediction of critical pharmacokinetic properties.
Intermune signed a multiyear license to use Qualyst's B-Clear® system for its drug discovery programs.
B-Clear offers research organizations the ability to generate physiologically-relevant data and enable decision making in areas related to hepatic transport and adverse drug interactions, helping to avoid costly drug development challenges and enabling better prediction of bioavailability, pharmacokinetics, species-specific drug dosing, and candidate selection.
The system is a sandwich-cultured hepatocyte system for the in vitro assessment and in vivo prediction of critical pharmacokinetic properties, including hepatobiliary disposition, hepatic uptake, hepatic accumulation, biliary clearance, and drug transport.